NCT01419964

Efficacy and Safety of ACH24 in the Treatment of Vitiligo

Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Parallel Group Study of the Efficacy and Safety of ACH24 in the Treatment of Vitiligo

• Status: Withdrawn
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Ache Laboratorios Farmaceuticos S.A. · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

This is a multicenter clinical trial, phase III, randomized, placebo-controlled, parallel group, enroll 94 patients, to assess the efficacy of ACH24 in the repigmentation of achromatic areas in patients with vitiligo.

Detailed description

To evaluate the efficacy and safety of ACH24 compared to placebo in the treatment of vitiligo.The present study aims to register a new product in the country, the ACH24 for the treatment of vitiligo.

Conditions

• Vitiligo

Interventions

Type	Name	Description
DRUG	Group 01	ACH24
DRUG	Group 02	Placebo

Timeline

• Start date: 2012-01-01
• Primary completion: 2013-12-01
• First posted: 2011-08-19
• Last updated: 2016-03-16

Locations

1 site across 1 country: Brazil